Overcoming tumor necrosis factor-α resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-α. Role of tumor necrosis factor-α mRNA down-regulation in tumor cell sensitization
Authors:
Abstract
Background. Previous studies have reported that glutathione plays a central role in a wide range of cellular functions, including protection, detoxification, transport, and metabolism. Buthionine sulfoximine (BSO), a specific inhibitor of γ‐glutamyl‐cysteine synthetase, depletes intracellular glutathione. The study investigates the cytotoxic effect of BSO and tumor necrosis factor‐α (TNF‐α) used in combination on TNF‐α‐resistant human renal and ovarian cancer cells. Methods. Cytotoxicity was determined by a 1‐day microculture tetrazolium dye assay. TNF‐α mRNA was examined by Northern blot analysis. Results. Combination treatment of TNF‐α‐resistant R4 and R11 human renal cell carcinoma cells with BSO and TNF‐α overcame their resistance to TNF‐α. In addition, the combination of BSO and TNF‐α resulted in a synergistic cytotoxic effect on TNF‐α‐resistant OVC‐8 and C30 human ovarian cancer cells. Treatment of R4, R11, and OVC‐8 cells with TNF‐α in combination with glutathione or N‐acetyl‐cysteine (NAC) showed an antagonistic cytotoxic effect. A possible mechanism of resistance to TNF‐α in tumor cells is the expression of TNF‐α mRNA or protein. R4 cells and OVC‐8 cells constitutively expressed mRNA for TNF‐α. Treatment of R4 cells or OVC‐8 cells with BSO down‐regulated the expression of TNF‐α mRNA; however, treatment with TNF‐α up‐regulated the expression of TNF‐α mRNA. When BSO was used in combination with TNF‐α, the level of TNF‐α mRNA enhanced by TNF‐α was markedly reduced. Incubation of R4 cells with glutathione or NAC also down‐regulated the expression of TNF‐α mRNA. R11 and C30 cells did not constitutively express mRNA for TNF‐α, and the BSO treatment had no effect on the TNF‐α mRNA level. Conclusions. This study demonstrates that the combination of BSO and TNF‐α can overcome the TNF‐α resistance of tumor cells and that depletion of intracellular glutathione and down‐regulation of TNF‐α mRNA by BSO may play a role in the enhanced cytotoxicity seen with the combination of BSO and TNF‐α. There may not be always a correlation between the expression of TNF‐α mRNA in tumor cells and their resistance to TNF‐α. The synergistic effect obtained with established renal cell carcinoma cells and ovarian cancer cells suggests that combination treatment with TNF‐α and BSO could have clinical application in the therapy of TNF‐α‐resistant tumors.Keywords
This publication has 29 references indexed in Scilit:
- Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor–alphaCancer, 1993
- Induction of Manganous Superoxide Dismutase by Tumor Necrosis Factor: Possible Protective MechanismScience, 1988
- A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.Journal of Clinical Oncology, 1988
- Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line.Proceedings of the National Academy of Sciences, 1987
- Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in VitroScience, 1985
- Tumor Necrosis Factor (TNF)Science, 1985
- Molecular Cloning of the Complementary DNA for Human Tumor Necrosis FactorScience, 1985
- Cloning and expression in Escherichia coli of the gene for human tumour necrosis factorNature, 1985
- Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.Proceedings of the National Academy of Sciences, 1983
- An endotoxin-induced serum factor that causes necrosis of tumors.Proceedings of the National Academy of Sciences, 1975